It is important to recognize that the higher risk of HF in EGFR-mutated NSCLC patients may stem from a combination of factors, including older age, pre-existing cardiac conditions, and other comorbidities commonly observed in real-world patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.